‌

‌
‌
‌
‌

‌

‌

‌
‌
‌

‌

‌
‌
‌

‌

‌

‌
‌
‌

‌

‌
‌
‌

Palicalm (PALIPERIDONE)

brandsClassPalicalm commonly prescribed forHow Palicalm worksHow long until Palicalm worksNotable Side EffectsLife Threatening Side Effectsweight gainsedationWhat to do about Palicalm side effectsusual dosage rangeDosage Formslong term usehabit formingRenal ImpairmentHepatic ImpairmentCardiac ImpairmentElderlyChildren and AdolescentsPregnancyBreast Feeding

THERAPEUTICS

brands

  • Palip XP
  • Paliris 3
  • Palicalm

Class

  • Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn)
  • Atypical antipsychotic (serotonin– dopamine antagonist; second-generation antipsychotic; also a mood stabilizer)

Palicalm commonly prescribed for

(Bold for FDA approved)

• Schizophrenia in adults (Invega, Invega Sustenna) and in patients ages 12 through 17 (Invega)
• Schizophrenia in patients who have been adequately treated with Invega Sustenna for at least 4 months (Invega Trinza)
• Schizophrenia in patients who have been adequately treated with Invega Sustenna for at least 4 months OR with Invega Trinza for at least one 3-month cycle (Invega Hafyera)
• Schizoaffective disorder (Invega, Invega Sustenna)

• Other psychotic disorders
• Acute mania/mixed mania
• Bipolar maintenance
• Treatment-resistant depression
• Behavioral disturbances in dementia
• Behavioral disturbances in children and adolescents
• Disorders associated with problems with impulse control
• Posttraumatic stress disorder

How Palicalm works

• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis and stabilizing affective symptoms

• Blocks serotonin 2A receptors, causing enhancement of dopamine release in certain brain regions and thus reducing motor side effects and possibly improving cognitive and affective symptoms

• Interactions at a myriad of other neurotransmitter receptors may contribute to paliperidone’s efficacy

• Serotonin 7 antagonist properties may contribute to antidepressant actions

How long until Palicalm works

• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior as well as on cognition

• Classically recommended to wait at least 4–6 weeks to determine efficacy of drug, but in practice some patients may require up to 16–20 weeks to show a good response, especially on negative or cognitive symptoms

SIDE EFFECTS

Notable Side Effects

• Dose-dependent drug-induced parkinsonism

• Hyperprolactinemia

• May increase risk for diabetes and dyslipidemia

• Sedation

• Tachycardia

• Hypersalivation

• Dose-dependent orthostatic hypotension

• Injection site reactions

• Tardive dyskinesia (reduced risk compared to conventional antipsychotics)

• Risk of potentially irreversible, involuntary dyskinetic movements may increase with cumulative dose and treatment duration

Life Threatening Side Effects

• Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients taking atypical antipsychotics

• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure

• Rare seizures

• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis

weight gain

common

common

sedation

common

common

What to do about Palicalm side effects

• Wait

• Wait

• Wait

• Anticholinergics may reduce drug-induced parkinsonism when present

• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia

• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia

• Metformin may help prevent or reverse antipsychotic-induced weight gain

• Switch to another atypical antipsychotic

DOSING AND USE

usual dosage range

• 6 mg/day (oral)

• 1-month injectable maintenance dose: 117 mg/month (range 39–234 mg/month (see Paliperidone Palmitate section after Pearls for dosing and use)

• 3-month injectable maintenance dose: 273–819 mg/3 months (see Paliperidone Palmitate section after Pearls for dosing and use)

• 6-month injectable maintenance dose: based on the previous once-a-month or every-3-month product dose

Dosage Forms

• Tablet (extended-release) 1.5 mg, 3 mg, 6 mg, 9 mg

• 1-month injection 39 mg, 78 mg, 117 mg, 156 mg, 234 mg

• 3-month injection 273 mg, 410 mg, 546 mg, 819 mg

• 6-month injection 1092 mg, 1560 mg

long term use

• Approved for maintenance in schizophrenia

• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years

habit forming

• No

SPECIAL POPULATIONS

Renal Impairment

• For mild impairment, maximum recommended dose 6 mg/day

• For moderate impairment, initial and maximum recommended dose 3 mg/day

• For severe impairment, initial dose 1.5 mg/ day; maximum recommended dose 3 mg/ day

Hepatic Impairment

• No dose adjustment necessary for mild to moderate impairment

• Use in individuals with severe hepatic impairment has not been studied

Cardiac Impairment

• Use in patients with cardiac impairment has not been studied, so use with caution because of risk of orthostatic hypotension

• Use with caution if patient is taking concomitant antihypertensive or alpha 1 antagonist

Elderly

• Some patients may tolerate lower doses better

• Although atypical antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation

• Elderly patients with dementia-related psychosis treated with atypical antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events

• Consider pimavanserin for dementia-related psychosis or Parkinson’s disease psychosis instead of an atypical antipsychotic

Children and Adolescents

• Safety and efficacy have not been established under age 12

• Adolescents <51 kg: initial 3 mg/day; recommended 3–6 mg/day; maximum 6 mg/day

• Adolescents >51 kg: initial 3 mg/day; recommended 3–12 mg/day; maximum 12 mg/day

• Children and adolescents using paliperidone may need to be monitored more often than adults and may tolerate lower doses better

Pregnancy

• Controlled studies have not been conducted in pregnant women

• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding

• When administered to rats during the period of organogenesis, there were no treatmentrelated effects at doses up to 10 times the maximum recommended human dose

• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary

• Paliperidone may be preferable to anticonvulsant mood stabilizers if treatment is required during pregnancy

• Effects of hyperprolactinemia on the fetus are unknown

Breast Feeding

• Some drug is found in mother’s breast milk

• Recommended either to discontinue drug or formula feed

• Infants of women who choose to breast feed while on paliperidone should be monitored for possible adverse effects; sedation, failure to thrive, jitteriness, and drug-induced parkinsonism (tremor and abnormal muscle movements) have been reported

Based on data Published online by Cambridge University Press

Compiled by Dr. Jash Ajmera